Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-TRA: Rivaroxaban for Left Atrial Thrombus Resolution
NCT01839357Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of rivaroxaban in left atrial thrombosis, Left atrial appendage thrombus, sponsored by Bayer. Started Aug 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
left atrial thrombosisLeft atrial appendage thrombus
Beyond the preview
Go deeper on NCT01839357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01839357.